Navigation Links
AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
Date:8/8/2012

REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard King, President and Chief Executive Officer of AcelRx, will present at the Canaccord Genuity 32nd Annual Healthcare Conference at the InterContinental Boston Hotel in Boston, MA.  The presentation is scheduled for Wednesday, August 15, 2012 at 8:00 a.m. ET/5:00 a.m. PT.

The presentation will be webcast live and can be accessed through the following link: http://wsw.com/webcast/canaccord6/acrx/.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. AcelRx plans to initiate a Phase 2 study, pending protocol approval, for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC. For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q for the three months ended March 31, 2012. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
2. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
3. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
5. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
6. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
7. Jazz Pharmaceuticals Announces Second Quarter 2012 Results
8. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
9. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
11. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. ... multi-product marketing agreement with development and manufacturing partner ... Under the terms of this agreement, Breckenridge will ... in the United States . ... tentatively-approved ANDA. The products cover a wide range ...
(Date:12/5/2016)... and PUNE, India , December ... report by Allied Market Research, titled, "Global Cancer Biomarkers Market ... revenue of cancer biomarkers market is projected to reach $15,737 ... CAGR of 13.3% from 2016 to 2022. Omic technologies segment ... 2015 and is expected to maintain its dominance during the ...
(Date:12/5/2016)... FRANCISCO , Dec. 5, 2016  Recently ... a methylation age predictor, known as Horvath,s Clock. ... offering a sample analysis service to academic and ... of any human sample, other than sperm. The ... to accurately estimate biological age versus chronological age ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” ... tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the social ... people will be diagnosed with epilepsy within their lifetime. With such a large ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... lines. The goal of Castlewood Treatment Centers has always been to promote the ... as many people as possible. In that spirit, Castlewood has announced two new ...
Breaking Medicine News(10 mins):